ViiV Healthcare, majority owned by GSK Plc (NYSE:GSK), with Pfizer Inc (NYSE:PFE) and Shionogi Limited as shareholders, revealed data from a planned interim analysis of the LATITUDE phase 3 trial. The data indicated that long-acting injectable antiretroviral treatment (ART) for HIV, Cabenuva (cabotegravir + rilpivirine), demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of ART adherence challenges. Related Content:Pfizer/GSK-Backed ViiV Healthcare’s HIV Drug Associated With Increased Resistance, WHO Report Says. Du…